Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC737754)

Trial Profile

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC737754)

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary) ; Doxorubicin; Ifosfamide
  • Indications Alveolar soft part sarcoma; Cancer metastases; Carcinoma; Chondrosarcoma; Clear cell sarcoma; Fibroma; Haemangiosarcoma; Histiocytoma; Leiomyosarcoma; Liposarcoma; Liver cancer; Malignant fibrous histiocytoma; Muscle tissue neoplasms; Nerve sheath neoplasms; Osteosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PAZNTIS
  • Most Recent Events

    • 31 Jul 2023 Results (As of December 31, 2021, n=85) assessing assessing Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma published in the Journal of Clinical Oncology
    • 27 Mar 2023 Results(n=85 from dose-finding and randomized arms of ARST1321) assessing wound complications following addition of pazopanib, a tyrosine kinase inhibitor (TKI), to neoadjuvant radiotherapy (RT) +/- chemotherapy for soft tissue sarcoma published in the Journal of Surgical Oncology
    • 07 Jun 2022 Results assessing outcomes following preoperative chemoradiation plus minus pazopanib in non-rhabdomyosarcoma soft tissue sarcoma presented at the 58th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top